GLOW vs KLOW Blend: Comparing Three- and Four-Peptide Preparations
GLOW and KLOW are the two blend names that come up most often in tissue-repair research discussion. The names are similar, the compositions overlap heavily, and the difference between them is exactly one peptide. That single addition is what separates the two, so it is worth understanding precisely what it contributes.
What each preparation contains
GLOW is conventionally a three-peptide preparation: GHK-Cu, BPC-157 and TB-500. The name is commonly read as an abbreviation drawn from its components.
KLOW is the same three components with KPV added, making it a four-peptide preparation. Our KLOW Blend is supplied at 50mg GHK-Cu, 10mg BPC-157, 10mg TB-500 and 10mg KPV.
| Component | GLOW | KLOW |
|---|---|---|
| GHK-Cu | Yes | Yes |
| BPC-157 | Yes | Yes |
| TB-500 | Yes | Yes |
| KPV | No | Yes |
| Component count | Three | Four |
What each component is studied for
GHK-Cu
A copper-binding tripeptide (glycyl-L-histidyl-L-lysine) that forms a complex with copper(II). Preclinical literature examines it in the context of extracellular matrix remodelling, including expression of collagen and metalloproteinase regulators. It is the highest-mass component of the blend by a wide margin.
BPC-157
A synthetic pentadecapeptide studied largely in relation to angiogenic signalling, with published rodent work reporting VEGFR2 pathway involvement in injured tissue.
TB-500
A synthetic fragment of thymosin beta-4, examined for actin-sequestering activity and its relationship to cell migration. Our TB-500 overview covers the parent protein in more detail.
KPV – the differentiator
KPV is a tripeptide (lysine-proline-valine) corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone. Unlike the other three, the literature on KPV centres on inflammatory signalling rather than on vascular supply, matrix deposition or cell motility. Published work examines effects on NF-kB pathway activity and on pro-inflammatory cytokine expression in intestinal and dermal models.
That is the substantive difference between the two preparations. GLOW combines three mechanisms concerned with rebuilding a tissue region. KLOW adds a fourth concerned with the inflammatory environment in which that rebuilding takes place.
Why the distinction matters for study design
If an experimental endpoint involves inflammatory markers, a three-component preparation and a four-component preparation are not interchangeable, and results from one should not be read across to the other. If the endpoints are purely structural, the practical difference narrows considerably.
There is also a straightforward methodological point about blends generally: a four-component preparation makes attribution harder. If an effect appears, isolating which component produced it requires the individual compounds. Many protocols therefore run a blend alongside single-compound arms using GHK-Cu, BPC-157, TB-500 and KPV separately.
Verifying composition
Blend composition is not standardised across suppliers. Two vials labelled KLOW can differ in the mass of each component, which makes the ratio a variable rather than a constant. The certificate of analysis for the specific lot is the only reliable statement of what a vial contains – our guide to third-party COAs explains what to look for. Further detail on this preparation is in the KLOW Blend research guide.
Frequently Asked Questions
What is the actual difference between GLOW and KLOW?
KPV. GLOW is conventionally GHK-Cu, BPC-157 and TB-500. KLOW is those three plus KPV, a tripeptide studied in relation to inflammatory signalling.
Is a four-peptide blend better than a three-peptide blend?
Neither is inherently better – they are studied for different things. Adding a component broadens what a preparation addresses but makes it harder to attribute any observed effect to a specific mechanism.
What is KPV derived from?
KPV corresponds to the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone. Published work examines it in relation to NF-kB signalling and pro-inflammatory cytokine expression.
Are blend ratios standardised between suppliers?
No. Composition varies by supplier, so the lot-specific certificate of analysis is the only reliable statement of what a given vial contains.
Why run single compounds alongside a blend?
Because a blend cannot tell you which component produced an observed effect. Single-compound arms are what make attribution possible.
For Research Use Only
All compounds discussed in this article are supplied strictly for laboratory research purposes. They are not drugs, foods, cosmetics, or dietary supplements, and are not intended to diagnose, treat, cure, or prevent any disease. They are not for human or veterinary consumption. This article summarises published preclinical literature for educational purposes and does not constitute guidance on use of any kind.